Search results for "lung cancer"
showing 10 items of 508 documents
LIQUID BIOPSY AS A DYNAMIC TOOL FOR LUNG CANCER MANAGEMENT: A FEASIBILITY STUDY FOR PLASMA-DERIVED EXOSOMAL miRNAs AND CELL-FREE DNA.
Early palliative care of non‑small cell lung cancer in the context of immunotherapy (Review)
2020
Abstract. The most common cause of mortality due to malig‑ nant neoplasms in the general population around the world is lung cancer. In the last 10 years, there has been an enormous improvement in the treatment of this disease, mainly due to the immunotherapy that activates the immune system to fight cancer. Patients with metastatic non‑small cell lung cancer are a special group of patients requiring not only cancer treatment but also considerable support in the treatment of cancer‑related problems, as well as comorbidities. Early palliative care is important in this area. In addition, there is certain evidence that medicines most commonly administered in palliative care may lower the effic…
Association of circulating tumor DNA (ctDNA) mutations and circulating miRNAs variations, through liquid biopsy, in Non-Small Cell Lung Cancer (NSCLC…
PREDICTIVE MODELS BASED ON RADIOMICS AND MACHINE LEARNING FOR LUNG CANCER RADIOTHERAPY DATA ANALYSIS
2020
Comorbidities and clinical outcomes of a lung cancer screening trial participants with chronic obstructive pulmonary disease in three-year follow-up
2022
To improve the effectiveness of lung cancer screening using low-dose computed tomography (LDCT), the presence of smoking-related comorbidities that may significantly affect mortality in this group should be taken into account. Material and methods: A questionnaire survey and spirometry tests were conducted in a group of 730 respondents as part of a lung cancer screening study between 2016 and 2018. People diagnosed with COPD underwent a three-year follow-up to assess the incidence of medical events. Results: Our study confirmed that cardiovascular diseases (CVDs) were the most common comorbidities in patients who were diagnosed with COPD and participated in LDCT lung cancer screening. Among…
Mutant HRAS as novel target for MEK and mTOR inhibitors.
2015
HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS as drug target has not been investigated so far. Here, we show that mutant HRAS hyperactivates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophageal cancer. HRAS mutation sensitized toward growth inhibition by the MEK inhibitors AZD6244, MEK162 and PD0325901. Further, we found that MEK inhibitors induce apoptosis in mutant HRAS cell lines but not in cell lines lacking RAS mutations. In addition, knockdown of HRAS by siRNA blocked cell growth in mutant HRAS cell lines. Inhibition of the PI3K pathway alone or in combination with MEK inhibitors did not alter signaling nor had an imp…
Thoracic Anesthesia during the 2019 Novel Coronavirus Infection Pandemic: 2021 Updated Recommendations for Airway Management by the EACTAIC Thoracic …
2021
Contains fulltext : 244115.pdf (Publisher’s version ) (Closed access) The novel coronavirus pandemic has radically changed the landscape of normal surgical practice. Lifesaving cancer surgery, however, remains a clinical priority, and there is an increasing need to fully define the optimal oncologic management of patients with varying stages of lung cancer, allowing prioritization of which thoracic procedures should be performed in the current era. Healthcare providers and managers should not ignore the risk of a bimodal peak of mortality in patients with lung cancer; an imminent spike due to mortality from acute coronavirus disease 2019 (COVID-19) infection, and a secondary peak reflecting…
Toxicity Profile and Adherence to the Pharmacotherapeutic Regimen of Gemcitabine–carboplatin in Non-small Cell Lung Cancer
2011
Objective: To analyse the relationship between doses of gemcitabine---carboplatin (GEM-CARBO) administered and incidence and level of haematological and renal toxicity, and the adherence to the treatment in patients with non-small cell lung cancer. Methods: Retrospective study, which lasted for 37 months. We were able to obtain the minimum set of data needed to carry out the follow-up with the help of Farmis-Oncofarm ® software and the medical and pharmacotherapeutic records. The haematological toxicity was assessed in accordance with the Common Toxicity Criteria 3.0. Renal toxicity was evaluated using serum creatinine levels and creatinine clearance. Results: Thirty-one patients were inclu…
Tendencias de la mortalidad por cáncer en españa, en especial del cáncer de pulmón, en comparación con otros países desarrollados
1994
ResumenSe estudia la evolución de la mortalidad global por cáncer en España (1970–1987), y especialmente por cáncer de pulmón, por sexos y grupos de edad, estableciendo comparaciones con otros países (EEUU, Inglaterra y Gales).En cuanto a la evolución de la mortalidad global por cáncer se observa que únicamente en las edades más juveniles se detectan descensos notables de la mortalidad, en tanto que, en los otros países con los que se compara, se observa también una disminución en edades más avanzadas. Asimismo, aunque las tasas de mortalidad por cáncer de pulmón en España tienen unos valores inferiores a los de los países mencionados, se observa un incremento de la mortalidad de ambos sexo…